Last reviewed · How we verify
Estrogen receptor positive advanced or metastatic breast cancer — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Orserdu | ELACESTRANT | Stemline Therap | Estrogen Receptor Antagonist [EPC] | Estrogen receptor | 2023-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Stemline Therap · 1 drug in Estrogen receptor positive advanced or metastatic breast cancer
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Estrogen receptor positive advanced or metastatic breast cancer:
- Estrogen receptor positive advanced or metastatic breast cancer treatment updates — RSS
- Estrogen receptor positive advanced or metastatic breast cancer treatment updates — Atom
- Estrogen receptor positive advanced or metastatic breast cancer treatment updates — JSON
Cite this brief
Drug Landscape (2026). Estrogen receptor positive advanced or metastatic breast cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/estrogen-receptor-positive-advanced-or-metastatic-breast-cancer. Accessed 2026-06-11.
Related
- Estrogen receptor positive advanced or metastatic breast cancer full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing